Do analysts rate PRFX or AMPE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PRFX or AMPE more profitable?

Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Ampio Pharmaceuticals N/A N/A N/A

Do analysts recommend AMPE or CERO?

CERo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 288,361.54%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Ampio Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better valuation and earnings, AMPE or CERO?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A CERo Therapeutics N/A N/A -$8.30M -$9.84 N/A

Is AMPE or CERO more profitable?

Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A CERo Therapeutics N/A N/A -209.40%

Which has higher valuation & earnings, HEPA or AMPE?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A

Is HEPA or AMPE more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hepion Pharmaceuticals N/A -812.56% -207.31% Ampio Pharmaceuticals N/A N/A N/A

Which has better valuation & earnings, BPTSY or AMPE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A

Is BPTSY or AMPE more profitable?

Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Ampio Pharmaceuticals N/A N/A N/A

Do analysts prefer CDT or AMPE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, CDT or AMPE?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$3.35 thousand N/A Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A

Is CDT or AMPE more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -72.25% -55.44% Ampio Pharmaceuticals N/A N/A N/A

Ampio Pharmaceuticals (AMPE) Competitors

$0.18 0.00 (0.00%)

As of 09/10/2026

Compare

AMPE vs. PRFX, CERO, HEPA, BPTSY, and CDT

Should you buy Ampio Pharmaceuticals stock or one of its competitors? Ampio Pharmaceuticals's main competitors and comparable companies include PainReform (PRFX), CERo Therapeutics (CERO), Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), and CDT Equity (CDT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ampio Pharmaceuticals compare to PainReform?

PainReform (NASDAQ:PRFX) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

37.3% of PainReform shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PainReform has higher revenue and earnings than Ampio Pharmaceuticals. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	37.41	-$5.02M	-$736.66	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

In the previous week, PainReform had 5 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 5 mentions for PainReform and 0 mentions for Ampio Pharmaceuticals. PainReform's average media sentiment score of 0.85 beat Ampio Pharmaceuticals' score of 0.00 indicating that PainReform is being referred to more favorably in the media.

Company	Overall Sentiment
PainReform	Positive
Ampio Pharmaceuticals	Neutral

PainReform has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Ampio Pharmaceuticals	N/A	N/A	N/A

Summary

PainReform beats Ampio Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to CERo Therapeutics?

Ampio Pharmaceuticals (NYSE:AMPE) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
CERo Therapeutics	Neutral

CERo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 288,361.54%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Ampio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Ampio Pharmaceuticals has a beta of 5.96, suggesting that its stock price is 496% more volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
CERo Therapeutics	N/A	N/A	-209.40%

Summary

CERo Therapeutics beats Ampio Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, suggesting that its stock price is 496% more volatile than the broader market.

Ampio Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Ampio Pharmaceuticals	N/A	N/A	N/A

In the previous week, Hepion Pharmaceuticals' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Hepion Pharmaceuticals	Neutral
Ampio Pharmaceuticals	Neutral

Summary

Ampio Pharmaceuticals beats Hepion Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Biophytis?

Biophytis (NASDAQ:BPTSY) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Ampio Pharmaceuticals	N/A	N/A	N/A

Biophytis has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market.

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Biophytis	Neutral
Ampio Pharmaceuticals	Neutral

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Ampio Pharmaceuticals beats Biophytis on 3 of the 4 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to CDT Equity?

CDT Equity (NASDAQ:CDT) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

CDT Equity has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, suggesting that its share price is 496% more volatile than the broader market.

Ampio Pharmaceuticals' return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-72.25%	-55.44%
Ampio Pharmaceuticals	N/A	N/A	N/A

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 7.3% of CDT Equity shares are held by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, CDT Equity had 4 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Ampio Pharmaceuticals. CDT Equity's average media sentiment score of 0.46 beat Ampio Pharmaceuticals' score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Neutral
Ampio Pharmaceuticals	Neutral

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Summary

Ampio Pharmaceuticals beats CDT Equity on 6 of the 11 factors compared between the two stocks.

Get Ampio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPE vs. The Competition

Export

Metric	Ampio Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$208K	$12.35B	$7.12B	$23.33B
Dividend Yield	N/A	2.62%	2.56%	3.53%
P/E Ratio	-0.02	797.19	272.98	28.72
Price / Sales	N/A	756.79	620.42	21.04
Price / Cash	N/A	90.55	77.33	34.42
Price / Book	0.05	10.39	10.33	4.74
Net Income	-$8.63M	$2.82B	$3.49B	$1.07B
7 Day Performance	N/A	-3.45%	-3.25%	-1.98%
1 Month Performance	N/A	1.35%	-0.23%	-2.52%
1 Year Performance	N/A	2.81%	17.33%	9.42%

Ampio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
PRFX PainReform	0.8871 of 5 stars	$0.95 +0.6%	N/A	-86.4%	$820K	$20K	N/A	4	News Coverage Short Interest Decrease Gap Up
CERO CERo Therapeutics	0.9511 of 5 stars	$0.01 -8.3%	$30.00 +272,627.3%	-99.8%	$788K	N/A	N/A	8
HEPA Hepion Pharmaceuticals	N/A	$0.06 -35.2%	N/A	-4.1%	$652K	N/A	N/A	20
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AMPE) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ampio Pharmaceuticals (AMPE) Competitors

AMPE vs. PRFX, CERO, HEPA, BPTSY, and CDT

How does Ampio Pharmaceuticals compare to PainReform?

Summary

How does Ampio Pharmaceuticals compare to CERo Therapeutics?

Summary

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Summary

How does Ampio Pharmaceuticals compare to Biophytis?

Summary

How does Ampio Pharmaceuticals compare to CDT Equity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPE vs. The Competition

Ampio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ampio Pharmaceuticals (AMPE) Competitors

AMPE vs. PRFX, CERO, HEPA, BPTSY, and CDT

How does Ampio Pharmaceuticals compare to PainReform?

Do institutionals & insiders hold more shares of PRFX or AMPE?

Which has better valuation and earnings, PRFX or AMPE?

Does the media favor PRFX or AMPE?

Which has more risk & volatility, PRFX or AMPE?

Do analysts rate PRFX or AMPE?

Is PRFX or AMPE more profitable?

Summary

How does Ampio Pharmaceuticals compare to CERo Therapeutics?

Does the media refer more to AMPE or CERO?

Do analysts recommend AMPE or CERO?

Which has more volatility & risk, AMPE or CERO?

Which has better valuation and earnings, AMPE or CERO?

Do insiders and institutionals believe in AMPE or CERO?

Is AMPE or CERO more profitable?

Summary

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Which has higher valuation & earnings, HEPA or AMPE?

Do institutionals and insiders have more ownership in HEPA or AMPE?

Which has more risk and volatility, HEPA or AMPE?

Is HEPA or AMPE more profitable?

Does the media prefer HEPA or AMPE?

Summary

How does Ampio Pharmaceuticals compare to Biophytis?

Which has better valuation & earnings, BPTSY or AMPE?

Is BPTSY or AMPE more profitable?

Which has more risk and volatility, BPTSY or AMPE?

Does the media refer more to BPTSY or AMPE?

Do institutionals & insiders have more ownership in BPTSY or AMPE?

Summary

How does Ampio Pharmaceuticals compare to CDT Equity?

Do analysts prefer CDT or AMPE?

Which has more risk and volatility, CDT or AMPE?

Is CDT or AMPE more profitable?

Do insiders & institutionals have more ownership in CDT or AMPE?

Does the media favor CDT or AMPE?

Which has stronger valuation & earnings, CDT or AMPE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPE vs. The Competition

Ampio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools